Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How to monitor SLE in routine clinical practice.

Literature DB >> 15769911

How to monitor SLE in routine clinical practice.

Abstract

A century ago syphilis was regarded as the great masquerader. Its modern equivalent is lupus. It may present to a wide range of specialists and its outcome, while much improved, remains uncertain in a significant number of patients.

Entities: Disease Species

Mesh：

Substances：
Biomarkers

Year: 2005 PMID： 15769911 PMCID： PMC1755465 DOI： 10.1136/ard.2003.015248

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

12 in total

1. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.

Authors: S Manzi; E N Meilahn; J E Rairie; C G Conte; T A Medsger; L Jansen-McWilliams; R B D'Agostino; L H Kuller
Journal: Am J Epidemiol Date: 1997-03-01 Impact factor: 4.897

2. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus.

Authors: P Rahman; D D Gladman; M B Urowitz; D Hallett; L S Tam
Journal: Lupus Date: 2001 Impact factor: 2.911

3. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.

Authors: S Lakshminarayanan; S Walsh; M Mohanraj; N Rothfield
Journal: J Rheumatol Date: 2001-01 Impact factor: 4.666

4. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.

Authors: D D Gladman; M B Urowitz; C H Goldsmith; P Fortin; E Ginzler; C Gordon; J G Hanly; D A Isenberg; K Kalunian; O Nived; M Petri; J Sanchez-Guerrero; M Snaith; G Sturfelt
Journal: Arthritis Rheum Date: 1997-05

Review 5. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice?

Authors: Inam Haq; D A Isenberg
Journal: Best Pract Res Clin Rheumatol Date: 2002-04 Impact factor: 4.098

6. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus.

Authors: T Stoll; C Gordon; B Seifert; K Richardson; J Malik; P A Bacon; D A Isenberg
Journal: J Rheumatol Date: 1997-08 Impact factor: 4.666

7. Outcome measures to be used in clinical trials in systemic lupus erythematosus.

Authors: V Strand; D Gladman; D Isenberg; M Petri; J Smolen; P Tugwell
Journal: J Rheumatol Date: 1999-02 Impact factor: 4.666

8. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

Authors: E M Hay; P A Bacon; C Gordon; D A Isenberg; P Maddison; M L Snaith; D P Symmons; N Viner; A Zoma
Journal: Q J Med Date: 1993-07

9. Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares.

Authors: B A Walz LeBlanc; D D Gladman; M B Urowitz
Journal: J Rheumatol Date: 1994-12 Impact factor: 4.666

10. The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.

Authors: W J Morrow; D J Williams; C Ferec; R Casburn-Budd; D A Isenberg; E Paice; M L Snaith; P Youinou; P Le Goff
Journal: Ann Rheum Dis Date: 1983-12 Impact factor: 19.103

11 in total

1. Systemic lupus erythematosus.

Authors: Maliha F Shaikh; Natasha Jordan; David P D'Cruz
Journal: Clin Med (Lond) Date: 2017-02 Impact factor: 2.659

2. A clinical overview of autoantibodies in general practice rheumatology.

Authors: Adrian Y S Lee; Eugene B H Ang
Journal: Br J Gen Pract Date: 2014-09 Impact factor: 5.386

3. C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.

Authors: Pavel A Nikitin; Eileen L Rose; Tony S Byun; Graham C Parry; Sandip Panicker
Journal: J Immunol Date: 2019-01-11 Impact factor: 5.422

4. Role of Cystatin C in Predicting Disease Activity and Flare-Up in Systemic Lupus Erythematosus: A Longitudinal Follow-Up Study.

Authors: Alimohammad Fatemi; Zahra Rahami; Abbas Smiley
Journal: Int J Prev Med Date: 2021-06-25

5. Nuclear Pore Protein p62 Autoantibodies in Systemic Lupus Erythematosus.

Authors: Doris M Kraemer; Hans-Peter Tony
Journal: Open Rheumatol J Date: 2010-05-13

6. Periodontal findings in systemic lupus erythematosus patients and healthy controls.

Authors: Khalid D Al-Mutairi; Mohammad S Al-Zahrani; Sami M Bahlas; Rayyan A Kayal; Khalid H Zawawi
Journal: Saudi Med J Date: 2015-04 Impact factor: 1.484

7. The Usefulness of Endothelial Cell Adhesion Molecules and Anti-C1q Antibody in Monitoring Systemic Lupus Erythematosus Disease Activity.

Authors: Hasni Mahayidin; Nurul Khaiza Yahya; Wan Syamimee Wan Ghazali; Asmahan Mohd Ismail; Wan Zuraida Wan Ab Hamid
Journal: Int Sch Res Notices Date: 2014-10-29